Vedolizumab for Inflammatory Bowel Disease: Two‐Year Results of the Initiative on Crohn and Colitis (ICC) Registry, A Nationwide Prospective Observational Cohort Study: ICC Registry – Vedolizumab

Prospective data of vedolizumab treatment for patients with inflammatory bowel disease (IBD) beyond 1 year of treatment is scarce but needed for clinical decision making. We prospectively enrolled 310 patients with IBD (191 with Crohn's disease (CD) and 119 patients with ulcerative colitis (UC)...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clin Pharmacol Ther
Hlavní autoři: Biemans, Vince B.C., van der Woude, C. Janneke, Dijkstra, Gerard, van der Meulen‐de Jong, Andrea E., Oldenburg, Bas, de Boer, Nanne K., Löwenberg, Mark, Srivastava, Nidhi, Bodelier, Alexander G.L., West, Rachel L., Jansen, Jeroen M., de Vries, Annemarie C., Haans, Jeoffrey J.L., de Jong, Dirk J., Pierik, Marie J., Hoentjen, Frank
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2019
Témata:
Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7232860/
https://ncbi.nlm.nih.gov/pubmed/31677154
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpt.1712
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky